HUP0302913A3 - Methods of inducing cancer cell death and tumor regression and preparation of pharmaceutical compositions suitable for treating the same - Google Patents

Methods of inducing cancer cell death and tumor regression and preparation of pharmaceutical compositions suitable for treating the same

Info

Publication number
HUP0302913A3
HUP0302913A3 HU0302913A HUP0302913A HUP0302913A3 HU P0302913 A3 HUP0302913 A3 HU P0302913A3 HU 0302913 A HU0302913 A HU 0302913A HU P0302913 A HUP0302913 A HU P0302913A HU P0302913 A3 HUP0302913 A3 HU P0302913A3
Authority
HU
Hungary
Prior art keywords
treating
preparation
methods
pharmaceutical compositions
cancer cell
Prior art date
Application number
HU0302913A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Daley George Q Weston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daley George Q Weston filed Critical Daley George Q Weston
Publication of HUP0302913A2 publication Critical patent/HUP0302913A2/hu
Publication of HUP0302913A3 publication Critical patent/HUP0302913A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0302913A 2000-10-05 2001-10-05 Methods of inducing cancer cell death and tumor regression and preparation of pharmaceutical compositions suitable for treating the same HUP0302913A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23824000P 2000-10-05 2000-10-05
PCT/US2001/042509 WO2002028381A2 (en) 2000-10-05 2001-10-05 Methods of inducing cancer cell death and tumor regression

Publications (2)

Publication Number Publication Date
HUP0302913A2 HUP0302913A2 (hu) 2003-12-29
HUP0302913A3 true HUP0302913A3 (en) 2005-05-30

Family

ID=22897049

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302913A HUP0302913A3 (en) 2000-10-05 2001-10-05 Methods of inducing cancer cell death and tumor regression and preparation of pharmaceutical compositions suitable for treating the same

Country Status (14)

Country Link
US (1) US6777415B2 (enExample)
EP (1) EP1322334A2 (enExample)
JP (1) JP2004510733A (enExample)
CN (1) CN1479630A (enExample)
AU (2) AU2002211862B2 (enExample)
BR (1) BR0114430A (enExample)
CA (1) CA2424797C (enExample)
HK (1) HK1052870A1 (enExample)
HU (1) HUP0302913A3 (enExample)
MX (1) MXPA03003011A (enExample)
NO (1) NO20031531L (enExample)
NZ (1) NZ524936A (enExample)
WO (1) WO2002028381A2 (enExample)
ZA (1) ZA200302523B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369138B2 (en) 1997-07-11 2002-04-09 Bridgestone Corporation Processability of silica-filled rubber stocks with reduced hysteresis
WO2008109417A1 (en) * 2007-03-02 2008-09-12 Case Western Reserve University Mgmt inhibitor combinations for the treatment of neoplastic disorders
WO2002028409A2 (en) * 2000-10-05 2002-04-11 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
US20040126755A1 (en) * 2001-08-29 2004-07-01 Stephan Dietrich A Gene expression based method for distinguishing metastatic from non-metastatic forms of a tumor, and use in designing therapeutic drugs
CN1617755A (zh) * 2001-11-30 2005-05-18 先灵公司 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
AU2003228225B2 (en) * 2002-03-01 2010-05-13 Roger Williams Hospital SHC protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US7691905B2 (en) * 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
CA2544421A1 (en) * 2003-11-06 2005-05-26 Schering Corporation Combination of a farnesyl transferase inhibitor with an antihormonal agent for the treatment of breast cancer
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20070148660A1 (en) * 2005-06-16 2007-06-28 The Regents Of The University Of California Treatment of maladaptive substance use with H-ras antagonists
JP2009511450A (ja) * 2005-10-07 2009-03-19 ノバルティス アクチエンゲゼルシャフト ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ
WO2007058965A1 (en) * 2005-11-11 2007-05-24 Roger Williams Hospital P66-shc as predictive marker in cancer treatment
CN102274513B (zh) * 2011-07-06 2013-02-20 南开大学 ERK1/2抑制剂通过刺激巨噬细胞干扰素γ表达抑制肿瘤生长
CN102626416B (zh) * 2012-05-11 2013-04-17 江苏省人民医院 他莫昔芬联合雷帕霉素、人参皂苷Rg3复合物在制备治疗肝癌药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2098198A1 (en) 1990-12-18 1992-06-18 Ann Christie King Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
EP0906099A4 (en) 1996-04-03 2001-02-07 Merck & Co Inc METHOD FOR TREATING CANCER
JP2000508335A (ja) * 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
CN1267291A (zh) 1997-06-17 2000-09-20 先灵公司 新的n－取代的脲的法呢基蛋白转移酶抑制剂
ATE218137T1 (de) * 1997-06-17 2002-06-15 Schering Corp Benzo(5,6)cyclohepta(1,2-b)pyridin derivate als farnesyl protein transferase inhibitoren
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
AU779008C (en) 1999-01-11 2005-06-30 Princeton University High affinity inhibitors for target validation and uses thereof
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
EP1181013B1 (en) * 1999-04-14 2006-10-11 Dana-Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
WO2002000024A1 (en) * 2000-06-30 2002-01-03 The Regents Of The University Of California New strategy for leukemia therapy
WO2002028409A2 (en) * 2000-10-05 2002-04-11 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors

Also Published As

Publication number Publication date
AU1186202A (en) 2002-04-15
US6777415B2 (en) 2004-08-17
CA2424797C (en) 2009-12-29
AU2002211862B2 (en) 2007-03-15
NO20031531D0 (no) 2003-04-04
ZA200302523B (en) 2004-08-24
MXPA03003011A (es) 2003-07-14
WO2002028381A2 (en) 2002-04-11
HUP0302913A2 (hu) 2003-12-29
US20020128280A1 (en) 2002-09-12
BR0114430A (pt) 2004-01-06
NO20031531L (no) 2003-06-05
JP2004510733A (ja) 2004-04-08
HK1052870A1 (zh) 2003-10-03
NZ524936A (en) 2005-08-26
EP1322334A2 (en) 2003-07-02
WO2002028381A3 (en) 2003-03-27
CN1479630A (zh) 2004-03-03
CA2424797A1 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
ZA200108258B (en) Methods of inducing cancer cell death and tumor regression.
AU6147401A (en) Compositions and methods for the treatment of cancer
HUP0301046A3 (en) Quinazoline derivatives for the treatment of tumours, process for their preparation and pharmaceutical compositions containing them
HUP0203968A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
HUP0302913A3 (en) Methods of inducing cancer cell death and tumor regression and preparation of pharmaceutical compositions suitable for treating the same
PL366626A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
HUP0102039A3 (en) Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby
PL354093A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
PL365244A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
HUP0400918A3 (en) Utilization of pyrazoline derivatives in the preparation of pharmaceutical compositions for the prevention and/or treatment of proliferative cell diseases
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
HUP0201187A3 (en) Use of ecteinascidin743 for producing pharmaceutical compositions suitable for treating cancer
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
EP1385465A4 (en) HETEROCYCLIC DERIVATIVE FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES
HUP0300848A3 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
EP1349485A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF OVARIAL CARCINOMA
IL143212A0 (en) Compositions and methods for the treatment of tumor

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees